Positive Results for a Dry Nasal Spray

The Sacramento Bee is reporting that Teva Respiratory's Phase III trial of their new beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol has seen positive results. The Phase III trial was testing the safety and efficacy of the treatment a "dry" nasal spray designed to avoid the post-nasal drip that comes with "wet" nasal sprays. The spray is designed to help in the treatment of seasonal allergic rhinitis (SAR), known more commonly simply as seasonal allergies.If the new spray passes future phases of testing it may serve as a big step forward for those suffering from seasonal allergies who find the post-nasal drip of "wet" sprays off putting. Treating allergic rhinitis can help avoid sinusitis and also with asthma management as allergic rhinitis can cause or worsen these ailments. Contact our office if you have questions or concerns about treatment for allergic rhinitis, sinusitis, or asthma.